Submission from Students for Sensible Drug Policy on the draft Misuse of Drugs Act 1971 (Amendment) Order 2026

I am writing to raise concerns about the proposed control of SR-17018 and related research compounds under the draft Misuse of Drugs Act 1971 (Amendment) Order 2026, and to request scrutiny of the supporting evidence, consultation process, and implications for legitimate scientific research.

Article 2(2)(a)(v) explicitly adds 5,6-dichloro desmethylchlorphine (SR-17018) to Class A. Article 2(2)(c) also introduces broader structural definitions covering related compounds. I would welcome clarification of their intended scope, including whether research compounds such as SR-15099 would be captured.

Protecting people from harmful synthetic opioids is an important public health objective. However, the evidence supporting control should distinguish between individual compounds. The ACMD's April 2026 seventh addendum identifies cychlorphine, spirochlorphine and chlorphine in its discussion of UK mortality data. Those findings warrant action, but do not themselves establish equivalent harms from SR-17018. I ask the Committee to seek a clear account of the evidence specific to SR-17018, including any verified deaths, hospitalisations or other serious adverse events, and how that evidence supports permanent Class A control.

The publicly available evidence also does not establish the prevalence, scale, or pattern of SR-17018 misuse. Isolated forensic detections and limited reports of availability do not, by themselves, demonstrate widespread misuse or quantify resulting harm. I therefore ask the Committee to request that the Home Office provide the compound-specific data underpinning its concerns about SR-17018 and related compounds proposed for control, including the frequency and geographical distribution of detections, documented patterns of misuse, and verified adverse events. The supporting assessment should distinguish evidence concerning each compound from conclusions inferred from other opioids, and clearly identify gaps in the available data.

Students for Sensible Drug Policy (SSDP) has raised closely related concerns in the United States. In a statement made in August 2026, SSDP described its joint administrative request with the Rights & Reason Project challenging SR-17018's emergency scheduling and highlighted the regulatory, financial, and legal barriers that scheduling can create for research. Although the US and UK legal frameworks differ, the underlying policy question is relevant: has the potential public health cost of delaying or deterring research been adequately considered?

The Explanatory Memorandum raises particular concerns. Paragraph 7.2 states that the two new generic definitions of orphines were excluded from consultation on legitimate uses because of the perceived urgency of control. The absence of an established medicinal use should not be treated as the absence of legitimate scientific use. Published studies found that SR-17018 suppressed morphine withdrawal while allowing analgesic tolerance to reverse, supporting further research into its potential for opioid use disorder treatment. Paragraph 9.1 also assumes that businesses with legitimate uses already hold the necessary licences or benefit from exemptions. I would welcome scrutiny of whether this adequately accounts for academic laboratories, new research programmes and prospective clinical development.

I therefore respectfully ask the Committee to seek clarification from the Home Office on:

- The evidence specific to SR-17018 supporting permanent Class A control, distinguished from evidence concerning other orphines.

- Whether researchers working directly with SR-17018 and related compounds were consulted, and how their evidence informed the proposal.
- Which established research compounds the generic definitions would capture, including SR-15099.
- The practical research arrangements under the accompanying scheduling regulations, including licensing costs, processing times, sourcing, importation and continuity of ongoing studies.
- Whether narrower provisions, research exemptions or other proportionate safeguards were considered, and how the effects on research will be monitored.

I ask the Committee to consider drawing the instrument to the special attention of the House because of these policy and evidential concerns, and to request a fuller explanation of the research implications before approval. Effective public protection should include preserving a workable route to establish whether compounds such as SR-17018 have therapeutic value.

Thank you for considering this submission. I apologize for submitting after the requested date, having overlooked the time difference. I would be grateful for acknowledgement of receipt and confirmation of whether it can still inform scrutiny at the Committee's upcoming meeting.

Jackson Rund

Vice Chair, Board of Directors

Vice Chair, Global Drug Policy Committee

Students for Sensible Drug Policy

14 October 2026

Response from the Home Office

As an opening point, the supply, production, importation, exportation and possession with intent to supply of SR-17018 have been specific offences since 11 June 2026, under the Misuse of Drugs Act 1971 (Temporary Class Drug) Order 2026 (SI 2026/613). That Order enables SR-17018 to be used legitimately, with provisions equivalent to Schedule 1. The Explanatory Memorandum for that Order set out the rationale and evidence base for controlling SR-17018 and the other six orphines.

- **What is the evidence specific to SR-17018 supporting permanent Class A control, distinguished from evidence concerning other orphines, including any verified deaths, hospitalisations or other adverse serious events?**

Ministers accepted the recommendation of the independent ACMD to control SR-17018. The basis for that recommendation, which Ministers accepted, was that the EU Drugs Agency (EUDA) identified SR-17018 as being present in EU drugs markets (please see paragraph 5.5 of the Explanatory Memorandum for SI 2026/613). We understand that there have been no more than a very small number of detections of SR-17018 in the UK.

- **If there is no or little such evidence relating to SR-17018 specifically, why is it being controlled?**

Given the identification by EUDA we are controlling SR-17018 to seek to prevent its use leading to deaths, hospitalisations and other adverse serious events. This is a standard approach in UK drug policymaking, and applies to some other controls within this instrument. We would draw the Committee's attention to section 1(2) of the Misuse of Drugs Act 1971:

"It shall be the duty of the Advisory Council to keep under review the situation in the United Kingdom with respect to drugs which are being ***or appear to them likely to be*** *misused and of which the misuse is having* ***or appears to them capable of having*** *harmful effects sufficient to constitute a social problem…"* [emphases added]

- **And why is it urgent to do so before standard policymaking steps such as consultation?**

The urgency derives from the risk to public health. It is usual practice not to consult (other than with the ACMD) on the controls of individual substances (as opposed to most generic definitions), because of the detailed work the ACMD undertakes.

- **Were researchers working directly with SR-17018 and related compounds consulted? If so, how did their evidence informed the proposal? If not, why not?**

As above, and for the reasons above, the Home Office did not consult.

- **Which established research compounds will the generic definitions capture?**
- **Will these include SR-15099?**

The generic definition for orphine-like materials (new sub-paragraph 1(h) of Part 1 of Schedule 2 to the 1971 Act) is thought to cover 167 substances, and the generic definition for spirorphine-like materials (new sub-paragraph 1(i)) is thought to cover 62. [A full list of these substances is contained in the Annex to this paper.]

They will include SR-15099.

There is no clear way to determine which of those is and is not an established research compound.

- **The EM states that "For the drugs with legitimate uses which are being controlled, it is assumed that businesses will already possess the required licence to utilise these drugs within the UK, or benefit from an exemption under the 2001 Regulations". Does this include academic laboratories, new research programmes and prospective clinical development?**

Yes

- **What practical research arrangements will apply; for example, licensing costs, processing times, sourcing, importation and continuity of ongoing studies?**

Researchers wishing to undertake work involving SR-17018 would be required to comply with the relevant licensing requirements under the Misuse of Drugs Act legislative framework.

Organisations which already have a domestic controlled drugs licence that authorises activity involving Schedule 1 substances would not have to take additional action in relation to orphines. Should they later need to renew their Schedule 1 licence to continue research with orphines and/or other Schedule 1 substances, they would need to follow the standard renewal process and pay the associated renewal fees. Those currently range from £326 to £1,371 where a compliance visit is necessary. As set out above, we forecast, and have proceeded on the basis that, organisations which need to undertake research with orphines will be in this position (see paragraph 16 of the Economic Note). Such licence holders would be able to continue their research activities without interruption, subject to the existing terms and conditions of their licence. They would continue to be able to source the substance from appropriately authorised domestic suppliers, subject to compliance with the relevant licensing requirements.

Where licence holders in this position would need to source the substance from an appropriately authorised international supplier, they would require an import authorisation. Those are issued on a 'one use' or single-consignment basis and currently cost £24. They are normally processed within ten working days. Exporting the substance overseas would require an export authorisation, whose nature, cost and processing times are the same as for import authorisations. Please see paragraphs 50-52 of the Economic Note for more information.

While we estimate that no organisations will require a new domestic licence as a result of these controls, we cannot be certain about this. If an organisation needed to conduct research into orphines and did not already possess a domestic licence for Schedule 1 substances, it would first have to apply to vary any existing licence for substances in other Schedules, or apply for a new licence if it had none for any Schedule. These applications are assessed on a case-by-case basis. When a paper-based assessment is sufficient, complete applications are normally processed within 8 to 10 weeks. Where a compliance visit is required, applicants are normally contacted within 16 weeks of receipt of a valid application to arrange a visit. Application costs range from £3,133 to £4,700 for a new licence.

Any researchers in this position should therefore allow sufficient time to obtain any necessary licences or licence variations before commencing work.

- **What are the potential implications, including for public health, of delaying or deterring research that involves SR-17018?**

We do not consider it likely that this control will delay or deter research into SR-17018. The need to apply for a £24 import or export authorisation, with a ten working day turnaround time, is unlikely to have those effects. As above, we do not anticipate that organisations will need to apply

for a new domestic licence, but should that be wrong, licensing has clear public health benefits because it requires licensees to follow a set of procedures to stop harmful substances being diverted to illicit use.

- **Do you agree that published studies suggest a potential role for SR-17018 in opioid disorder treatment?**

Students for Sensible Drug Policy has not cited specific studies, so we cannot comment. We acknowledge that any controlled substance may have legitimate research uses, and inclusion within Schedule 1 enables such uses to continue with a Home Office licence. Should SR-17018 in future be authorised for medicinal use, then the Home Office would be able to move it to a different schedule (following consultation with the ACMD and with the approval of Parliament).

- **Were narrower provisions, research exemptions or other proportionate safeguards considered?**

We are not clear what these narrower provisions or safeguards would be. Control under the Misuse of Drugs Act 1971 is the standard means of addressing the use of harmful substances, as it enables criminal prosecution. The range of relevant provisions which flow from such controls depends on the schedule in which a substance is placed. Schedule 1 is the relevant schedule for substances with only research uses, and no current non-research uses have been identified for SR-17018. Research involving Schedule 1 substances can be pursued with a Home Office licence. Please see paragraphs 5.7, 5.8 and 6.4 of the Explanatory Memorandum for more information. Research can be pursued under a Home Office licence.

25 September and 20 October

Annex: Substances covered by the generic definitions for orphine-like materials and spirorphine-like materials

Orphine-like materials: IUPAC names

3-[1-(4-oxo-3,3-diphenylhexyl)piperidin-4-yl]-1H-benzimidazol-2-one
3-[3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]propanenitrile
3-[3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]propanenitrile
3-(1-benzylpiperidin-4-yl)-1H-benzimidazol-2-one
4-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]-2,2-diphenylbutanenitrile
3-(1-benzylpiperidin-1-ium-4-yl)-1H-benzimidazol-2-one
3-[1-[(4-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
1-acetyl-3-[1-(3,3-diphenylpropyl)piperidin-4-yl]benzimidazol-2-one
3-[1-[1-(2-chlorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]piperidin-4-yl]-5-methyl-1H-benzimidazol-2-one
3-[1-[(2-chloro-4-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(6-bromo-1,3-benzodioxol-5-yl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-chloro-4-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-5,6-dimethyl-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-6-chloro-1H-benzimidazol-2-one
3-[1-[(4-tert-butylphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-(1-phenylethyl)piperidin-4-yl]-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-1H-benzimidazol-2-one;oxalic acid
3-(1-benzylpiperidin-4-yl)-6-methyl-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-benzimidazol-2-one
3-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[[3-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-(2,3-dihydro-1-benzofuran-5-ylmethyl)piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2,4-difluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[2-oxo-3-[1-(4-oxo-3,3-diphenylhexyl)piperidin-4-yl]benzimidazol-1-yl]propanenitrile
3-[1-[(2-chloro-4-methylphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-methylphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(5-chloro-2-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2,3-difluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2,5-difluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(5-fluoro-2-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3-fluoro-4-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3-iodophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-bromophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3-bromo-4-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-propan-2-yloxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one

3-(1-benzylpiperidin-4-yl)-7-fluoro-1H-benzimidazol-2-one
3-[1-[1-(2,6-difluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3-ethoxy-4-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[[3,5-di(propan-2-yloxy)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(1R)-1-(2,6-difluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(1R)-1-(2,6-difluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-6-fluoro-1H-benzimidazol-2-one
4-[4-(3-methyl-2-oxobenzimidazol-1-yl)piperidin-1-yl]-2,2-diphenylbutanenitrile
3-(1-benzylpiperidin-4-yl)-6-chloro-1H-benzimidazol-2-one
3-[1-[(2-chloro-4-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
1-(1-benzylpiperidin-4-yl)-3-methylbenzimidazol-2-one
3-[1-[(3-ethoxy-4-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one
3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one
3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-6-chloro-1H-benzimidazol-2-one
7-chloro-3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
5,6-dichloro-3-[1-[(4-chloro-2-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one
5-bromo-3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-5-chloro-1H-benzimidazol-2-one
3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-5-chloro-1H-benzimidazol-2-one
5,6-dichloro-3-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
6-chloro-3-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
5-chloro-3-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
5,6-dichloro-3-[1-[(2-fluoro-4-methylphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-6-methyl-1H-benzimidazol-2-one
3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-7-chloro-1H-benzimidazol-2-one
7-chloro-3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-bromophenyl)methyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one
3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-6-chloro-1H-benzimidazol-2-one
5,7-dichloro-3-[1-[1-(4-methoxyphenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-7-chloro-1H-benzimidazol-2-one
1-[1-[(4-bromophenyl)methyl]piperidin-4-yl]-5,6-dichloro-3-methylbenzimidazol-2-one
3-[1-[1-(4-bromo-2-fluorophenyl)ethyl]piperidin-4-yl]-6-chloro-1H-benzimidazol-2-one
5-bromo-3-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
6-chloro-3-[1-[1-[4-(trifluoromethyl)phenyl]ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
5-chloro-3-[1-[(4-chloro-2-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
5-chloro-3-[1-[1-[4-(trifluoromethyl)phenyl]ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-bromophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-7-chloro-1H-benzimidazol-2-one
3-[1-[1-(4-bromo-2-fluorophenyl)ethyl]piperidin-4-yl]-7-chloro-1H-benzimidazol-2-one
7-chloro-3-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-5-fluoro-1H-benzimidazol-2-one
3-[1-[[3-ethoxy-4-(2-methylpropoxy)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3,4-diethoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3,5-diethoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3-butoxy-4-methoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-chloro-3,5-diethoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-chloro-3-ethoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3-ethoxy-4-propan-2-yloxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[[4-methoxy-3-(2-methylpropoxy)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3,5-diethoxy-4-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-methoxy-3-propoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-bromo-3,5-diethoxyphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one

3-[1-[1-(4-methoxyphenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
6-bromo-3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-6-methoxy-1H-benzimidazol-2-one
3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-6-fluoro-1H-benzimidazol-2-one
4-chloro-3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-bromo-2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-chlorophenyl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-5,7-dichloro-1H-benzimidazol-2-one
3-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(1,3-benzodioxol-5-yl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-ethoxyphenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-chloro-2-methylphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-4,6,7-trichloro-1H-benzimidazol-2-one
3-[1-[(3-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
5-chloro-3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-propan-2-yloxyphenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
6-chloro-3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
5,6-dichloro-3-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(4-butylphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[3-(1-benzylpiperidin-4-yl)-2-oxobenzimidazol-1-yl]propanenitrile
1-(bromomethyl)-3-iodobenzene;(2,6-dichlorophenyl)boronic acid;8-[[3-(2,6-dichlorophenyl)phenyl]methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;3-[1-[[3-(2,6-dichlorophenyl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one;8-[(3-iodophenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;3-[1-[(3-iodophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one;1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;3-piperidin-4-yl-1H-benzimidazol-2-one
1-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-4-chloro-3H-indol-2-one;1-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-6-chloro-3H-indol-2-one;3-[1-[(4-bromophenyl)methyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one;5-chloro-1-[1-[1-[4-(difluoromethoxy)phenyl]ethyl]piperidin-4-yl]-3H-indol-2-one;4-chloro-1-[1-[1-[4-(trifluoromethoxy)phenyl]ethyl]piperidin-4-yl]-3H-indol-2-one;6-chloro-3-[1-[1-[4-(trifluoromethyl)phenyl]ethyl]piperidin-4-yl]-1H-benzimidazol-2-one;5,6-dichloro-1-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-3H-indol-2-one
5-bromo-3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one;3-[1-[1-(4-bromo-2-fluorophenyl)ethyl]piperidin-4-yl]-6-chloro-1H-benzimidazol-2-one;3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one;3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-5-chloro-1H-benzimidazol-2-one;3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one;6-chloro-3-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one;5-chloro-3-[1-[1-[4-(trifluoromethyl)phenyl]ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
1-benzyl-N-(5-chloro-2-nitrophenyl)piperidin-4-amine;1-benzylpiperidin-4-amine;2-N-(1-benzylpiperidin-4-yl)-4-chlorobenzene-1,2-diamine;3-(1-benzylpiperidin-4-yl)-5-chloro-1H-benzimidazol-2-one;chloro(methylchloranuidyl)methane;5-chloro-3-piperidin-4-yl-1H-benzimidazol-2-one;deuterio(iodo)methane;2,4-dichloro-1-nitrobenzene;hydride;oxido formate
1-(1-benzylpiperidin-4-yl)-3-methylbenzimidazol-2-one
3-[1-[1-(4-bromo-2-fluorophenyl)ethyl]piperidin-4-yl]-6-chloro-1H-benzimidazol-2-one;3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-6-chloro-1H-benzimidazol-2-one;3-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one;3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-5-chloro-1H-benzimidazol-2-one;3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one;6-chloro-3-[1-[1-(4-ethylsulfanylphenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one

5-bromo-3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one;3-[1-[1-(4-bromo-2-fluorophenyl)ethyl]piperidin-4-yl]-7-chloro-1H-benzimidazol-2-one;3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-6-chloro-1H-benzimidazol-2-one;3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-7-chloro-1H-benzimidazol-2-one;5-chloro-3-[1-[1-[4-(trifluoromethyl)phenyl]ethyl]piperidin-4-yl]-1H-benzimidazol-2-one;6-chloro-3-[1-[1-[4-(trifluoromethyl)phenyl]ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
6-bromo-1-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-3H-indol-2-one;6-bromo-1-[1-[1-[4-(trifluoromethoxy)phenyl]ethyl]piperidin-4-yl]-3H-indol-2-one;6-chloro-1-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-3H-indol-2-one;7-chloro-3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one;7-chloro-3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one;5,6-dichloro-1-[1-[(2-fluoro-4-methylphenyl)methyl]piperidin-4-yl]-3H-indol-2-one;4,6-dichloro-1-[1-[1-(4-methoxyphenyl)ethyl]piperidin-4-yl]-3H-indol-2-one
6-bromo-1-[1-[1-(4-chloro-2-fluorophenyl)ethyl]piperidin-4-yl]-3H-indol-2-one;6-bromo-1-[1-[1-[4-(trifluoromethoxy)phenyl]ethyl]piperidin-4-yl]-3H-indol-2-one;6-chloro-1-[1-[(4-chloro-2-fluorophenyl)methyl]piperidin-4-yl]-3H-indol-2-one;7-chloro-3-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one;7-chloro-3-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one;5,6-dichloro-1-[1-[(2-fluoro-4-methylphenyl)methyl]piperidin-4-yl]-3H-indol-2-one;4,6-dichloro-1-[1-[1-(4-methoxyphenyl)ethyl]piperidin-4-yl]-3H-indol-2-one
1-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-4-chloro-3H-indol-2-one;1-[1-[(4-bromo-2-fluorophenyl)methyl]piperidin-4-yl]-6-chloro-3H-indol-2-one;3-[1-[(4-bromophenyl)methyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one;5-chloro-1-[1-[1-[4-(difluoromethoxy)phenyl]ethyl]piperidin-4-yl]-3H-indol-2-one;4-chloro-1-[1-[1-[4-(trifluoromethoxy)phenyl]ethyl]piperidin-4-yl]-3H-indol-2-one;5,6-dichloro-3-[1-[(4-chloro-2-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one;5,6-dichloro-1-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-3H-indol-2-one
1-acetyl-3-(1-benzylpiperidin-4-yl)benzimidazol-2-one
3-[1-[1-(4-iodophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one
3-[1-[2-fluoro-6-(trifluoromethyl)benzenecarboximidoyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[(2-chloro-4-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one;ethane
5,6-dichloro-3-[1-[(2-fluorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-(1-benzyl-3,3,4,5,5-pentadeuteriopiperidin-4-yl)-1H-benzimidazol-2-one
1-(1-benzylpiperidin-4-yl)-3-propanoylbenzimidazol-2-one
1-methyl-3-[1-[(4-methylphenyl)methyl]piperidin-4-yl]benzimidazol-2-one
1-methyl-3-[1-[(3-methylphenyl)methyl]piperidin-4-yl]benzimidazol-2-one
1-methyl-3-[1-[(2-methylphenyl)methyl]piperidin-4-yl]benzimidazol-2-one
3-[1-[(1R)-1-(2-chlorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
6-chloro-3-[1-[1-(4-methylphenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-methylphenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-methylphenyl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-[1-(4-methylphenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
1-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-3-methylbenzimidazol-2-one
3-[1-[1-(4-fluorophenyl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-(1-phenylpropyl)piperidin-4-yl]-1H-benzimidazol-2-one
3-[1-(1-phenylbutyl)piperidin-4-yl]-1H-benzimidazol-2-one
1-[1-[(3,5-difluorophenyl)methyl]piperidin-4-yl]-3-methylbenzimidazol-2-one
6-chloro-3-[1-[(4-methylphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one
1-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-3-methylbenzimidazol-2-one
1-[1-[(4-methoxyphenyl)methyl]piperidin-4-yl]-3-methylbenzimidazol-2-one
1-[1-[(3-chlorophenyl)methyl]piperidin-4-yl]-3-methylbenzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-5,7-dimethyl-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-5-methyl-1H-benzimidazol-2-one
3-(1-benzylpiperidin-4-yl)-6-methoxy-1H-benzimidazol-2-one
6-chloro-3-[1-[(2-methylphenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one

1-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]-3-methylbenzimidazol-2-one
1-[1-[(2-methoxyphenyl)methyl]piperidin-4-yl]-3-methylbenzimidazol-2-one

Spirorphine-like materials: IUPAC names

4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2,2-diphenylbutanenitrile
8-benzyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[1-(4-methylphenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[1-(4-chlorophenyl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-(4-oxo-3,3-diphenylhexyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(4-fluorophenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-(3,3-diphenylpropyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(4-chlorophenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(4-methoxyphenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[1-(2-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-(1,3-benzodioxol-5-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[[3-(chloromethyl)phenyl]methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(4-bromophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-[1-(4-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(4-bromophenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(4-methylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-[(2-methylphenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(4-methylphenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
1-(4-fluorophenyl)-8-[(2,3,4,5,6-pentamethylphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-4-one
8-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]-1-(4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-[(4-chlorophenyl)methyl]-1-(4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(3-methoxyphenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(2,6-dichlorophenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(2-chlorophenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
1-phenyl-8-(1-phenylethyl)-1,3,8-triazaspiro[4.5]decan-4-one
1-phenyl-8-(1-phenylpropyl)-1,3,8-triazaspiro[4.5]decan-4-one
1-phenyl-8-(1-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(3-chlorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(4-chlorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(3,4-difluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-[(3-iodophenyl)methyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(4-chlorophenyl)methyl]-1-(2-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
1-phenyl-8-[[2-(trifluoromethyl)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-4-one
8-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(2-methylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-[(1R)-1-(4-chlorophenyl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-[(1R)-1-(4-chlorophenyl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(4-iodophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(3,5-dichloro-4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(3-bromophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(3-chloro-5-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(2-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]decan-4-one
4-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2,2-diphenylbutanenitrile

8-benzyl-1-(4-methoxyphenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-benzyl-1-(4-propan-2-ylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one
8-(3,3-diphenylpropyl)-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
4-[2-(aminomethyl)phenyl]-1-[bis(2-bromophenyl)methyl]piperidin-4-ol;4-[2-(aminomethyl)phenyl]-1-[bis(2-chlorophenyl)methyl]piperidin-4-ol;4-[2-(aminomethyl)phenyl]-1-[bis(2-fluorophenyl)methyl]piperidin-4-ol;8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol;1-[bis(2-chlorophenyl)methyl]-4-phenylpiperidin-4-ol;8-[1-(2-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;8-[1-(4-fluorophenyl)pentyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;1-[(2-methylphenyl)-phenylmethyl]-4-phenylpiperidin-4-ol
8-[1-(2-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;hydrogen
4-bromo-2,2-diphenylbutanenitrile;4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2,2-diphenylbutanenitrile;1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
1-benzyl-4-(3,5-dichloro-4-fluoroanilino)piperidine-4-carbonitrile;1-benzyl-4-(3,5-dichloro-4-fluoroanilino)piperidine-4-carboxamide;8-benzyl-1-(3,5-dichloro-4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one;8-benzyl-1-(3,5-dichloro-4-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-2-en-4-one;1-benzylpiperidin-4-one;1-chloroethyl carbonochloridate;3,5-dichloro-4-fluoroaniline;1-(3,5-dichloro-4-fluorophenyl)-1,3,8-triazaspiro[4.5]decan-4-one
4-[2-(aminomethyl)phenyl]-1-[bis(2-bromophenyl)methyl]piperidin-4-ol;4-[2-(aminomethyl)phenyl]-1-[bis(2-chlorophenyl)methyl]piperidin-4-ol;4-[2-(aminomethyl)phenyl]-1-[bis(2-fluorophenyl)methyl]piperidin-4-ol;8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol;1-[bis(2-chlorophenyl)methyl]-4-phenylpiperidin-4-ol;8-[bis(2-fluorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol;8-[1-(2-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;8-[1-(4-fluorophenyl)pentyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;1-[(2-methylphenyl)-phenylmethyl]-4-phenylpiperidin-4-ol
4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2,2-diphenylbutanenitrile
4-bromo-2,2-diphenylbutanenitrile;4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2,2-diphenylbutanenitrile;1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
1-benzyl-4-(4-methylanilino)piperidine-4-carbonitrile;1-benzyl-4-(4-methylanilino)piperidine-4-carboxamide;8-benzyl-1-(4-methylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one;8-benzyl-1-(4-methylphenyl)-1,3,8-triazaspiro[4.5]dec-2-en-4-one;1-benzylpiperidin-4-one;1-chloroethyl carbonochloridate;4-methylaniline;1-(4-methylphenyl)-1,3,8-triazaspiro[4.5]decan-4-one
4-[2-(aminomethyl)phenyl]-1-[bis(2-bromophenyl)methyl]piperidin-4-ol;4-[2-(aminomethyl)phenyl]-1-[bis(2-fluorophenyl)methyl]piperidin-4-ol;8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol;8-[bis(2-fluorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol;8-[1-(2-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;8-[1-(4-fluorophenyl)pentyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
azido(trimethyl)silane;8-[3,3-diphenyl-3-(2H-tetrazol-5-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2,2-diphenylbutanenitrile
4-[2-(aminomethyl)phenyl]-1-[bis(2-bromophenyl)methyl]piperidin-4-ol;4-[2-(aminomethyl)phenyl]-1-[bis(2-fluorophenyl)methyl]piperidin-4-ol;8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol;8-[bis(2-fluorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol;8-[1-(2-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one